Bluebird Bio (NASDAQ: BLUE)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Bluebird Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Bluebird Bio Company Info
Bluebird Bio is a development-stage biotechnology company focused on gene therapy, gene editing, and cancer immunotherapy.
News & Analysis
2 Biotech Stocks That Could Soar in December
These two biotechs have important catalysts coming up in December.
Why Bluebird Bio Stock Soared 7% Higher on Tuesday
The company posted some encouraging numbers and said it had sufficient resources to take care of financial obligations through the second quarter of 2024.
Is Bluebird Bio Stock a Buy?
This biotech looks cheap, but is it a value trap?
Where Will Bluebird Bio Be in 1 Year?
Things could get better for the biotech, but they could also get worse.
More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics
These companies are innovators, something that can prove highly lucrative.
2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street
Find out why analysts have such high expectations for these stocks.
Is Bluebird Bio a Bargain Buy in September?
With multiple near-term growth catalysts in play, expectations are already high.
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.